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MicroRNA29a regulates IL-33-mediated tissue
remodelling in tendon disease
Neal L. Millar1, Derek S. Gilchrist1, Moeed Akbar1, James H. Reilly1, Shauna C. Kerr1, Abigail L. Campbell1,
George A.C. Murrell2, Foo Y. Liew1,3, Mariola Kurowska-Stolarska1 & Iain B. McInnes1
MicroRNA (miRNA) has the potential for cross-regulation and functional integration of
discrete biological processes during complex physiological events. Utilizing the common
human condition tendinopathy as a model system to explore the cross-regulation of
immediate inﬂammation and matrix synthesis by miRNA we observed that elevated IL-33
expression is a characteristic of early tendinopathy. Using in vitro tenocyte cultures and in vivo
models of tendon damage, we demonstrate that such IL-33 expression plays a pivotal role
in the transition from type 1 to type 3 collagen (Col3) synthesis and thus early tendon
remodelling. Both IL-33 effector function, via its decoy receptor sST2, and Col3 synthesis are
regulated by miRNA29a. Downregulation of miRNA29a in human tenocytes is sufﬁcient
to induce an increase in Col3 expression. These data provide a molecular mechanism of
miRNA-mediated integration of the early pathophysiologic events that facilitate tissue
remodelling in human tendon after injury.
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D
ysregulated tissue repair and inﬂammation characterize
many common musculoskeletal pathologies1, including
tendon disorders. Tendinopathies represent a common
precipitant for musculoskeletal consultation in primary care2,3
and comprise 30–50% of all sports injuries3. Tendinopathy is
characterized by altered collagen production from subtype 1 to 3
resulting in a decrease in tensile strength that can presage clinical
tendon rupture4. Inﬂammatory mediators are considered crucial
to the onset and perpetuation of tendinopathy5. Expression of
various cytokines has been demonstrated in inﬂammatory cell
lineages and tenocytes suggesting that both inﬁltrating and
resident populations participate in pathology6–9. Mechanical
properties of healing tendons in interleukin (IL)-6-deﬁcient mice
are inferior compared with normal controls10, while tumour
necrosis factor-a blockade improves the strength of tendon–bone
healing in a rat tendon injury model11. While these data raise the
intriguing possibility that cytokine targeting could offer
therapeutic utility, there is currently insufﬁcient mechanistic
understanding of cytokine/matrix biology in tendon diseases to
manifest this possibility in practice.
IL-33 is a member of the IL-1 cytokine family that plays a
major role in innate and acquired immune responses. IL-33 is
expressed in endothelial cells and ﬁbroblasts, co-located with
chromatin in the nucleus12. IL-33 is released following cellular
damage13 and biomechanical overload14, and is thus considered
an ‘alarmin’15. It has been implicated in a variety of inﬂammatory
pathologies including pulmonary, cutaneous and articular
diseases16. IL-33 functions via its cognate receptor ST2 that
exists in membrane-bound (mST2) or soluble decoy form (sST2)
and signals via a canonical IL-1R signalling cascade. Cytokines
are often regulated at the post-transcriptional level by miRNA
that control the gene expression by translational suppression and
destabilization of target mRNAs17. miRNA networks are
emerging as key homeostatic regulators of tissue repair with
fundamental roles proposed in stem cell biology, inﬂammation,
hypoxia response and angiogenesis18.
On the basis of the emerging role of ﬁbroblast-derived IL-33
in inﬂammatory19,20 and ﬁbrotic disorders21 and previous
investigations showing increased inﬂammatory leukocyte
inﬁltration in torn rotator cuff tendons22, we hypothesized that
the IL-33/ST2 signalling pathway might play a signiﬁcant role in
tendon pathology. Our data derived in animal and human models
of tendinopathy collectively suggest that the IL-33/ST2 system
functions as an alarmin in tendon by triggering inﬂammation and
switching collagen production towards biomechanically inferior
collagen III synthesis, thus contributing to the severity of
tendinopathy. Importantly, we found that miR-29a acts as a
critical regulator of tenocyte biology by integrating IL-33 effector
function and collagen matrix changes. This provides a novel
insight into the coordinated regulation of disparate biochemical
pathways by an miRNA to thereby modulate emerging tissue
pathology.
Results
IL-33 and ST2 expression in human tendinopathy. We ﬁrst
investigated IL-33 expression in human tendinopathy using our
previously developed model23. IL33, soluble and membrane-
bound ST2 transcripts were signiﬁcantly upregulated in early
tendinopathy compared with control or torn tendon biopsies
(Fig. 1a–c). Early tendinopathy tissues exhibited signiﬁcantly
greater staining for IL-33 and ST2 compared with torn tendon or
control biopsies (Fig. 1d). Staining was prominent in endothelial
cells (CD34þ ) and particularly ﬁbroblast-like cells, namely
tenocytes, which are considered pivotal to the regulation
of early tendinopathy (Supplementary Fig. 1a,b). In parallel,
in vitro-cultured tenocytes expressed nuclear IL-33 that was
upregulated at both the mRNA and protein levels following
stimulation by TNF-a and IL-1b (Fig. 1e,f). In contrast, ST2 was
constitutively expressed in both resting and unstimulated
tenocytes (Supplementary Fig. 1c).
IL-33 regulates tenocyte collagen matrix and cytokine synthesis.
Matrix dysregulation towards collagen 3 (Col3) expression is a
key early phenotypic change in tendinopathy thereby hastening
repair; Col3 is however biomechanically inferior4. IL-33 induced
dose- and time-dependent upregulation of total collagen protein
(Supplementary Fig. 1d), accounted for by an increased
expression of type I but particularly type III collagen mRNA
and protein (Fig. 1g–i, Supplementary Fig. 1e). Following
array analysis (Supplementary Fig. 2a–c) and consistent with
reported IL-33 downstream signalling12,16. IL-33-induced
collagen expression was abrogated by ERK and NFkB
inhibition (Supplementary Fig. 2d,e). Recombinant IL-33 also
signiﬁcantly elevated the production of IL-6, IL-8 and monocyte
chemoattractant protein-1, which was abrogated by NF-kB
inhibition (Supplementary Fig. 2f), suggesting that IL-33
operates in tenocytes via its canonical IL-1R signalling pathway.
Modelling IL-33/ST2 pathway in vivo following tendon injury.
We extended these observations to a well-established in vivo
murine model of tendon injury. IL-33 mRNA and protein were
elevated on days 1 and 3 post tendon injury in wild-type (WT)
BALB/c mice (Fig. 2a–c). This was signiﬁcantly reduced in
injured St2 / BALB/c mice suggesting autocrine regulation.
Soluble St2 was signiﬁcantly upregulated at all time points post
injury in WT mice compared with uninjured controls (Fig. 2b).
No signiﬁcant changes in Il33 or St2 transcript were found in WT
mice at days 7 or 21 post injury, or for Il33 expression in St2 /
mice, suggesting that the impact of IL-33 expression is manifest
early, in keeping with ‘alarmin’ type activity in tendon injury/
repair.
Analysis of collagen synthesis revealed signiﬁcantly greater
expression of collagen 3 at all time points post injury in WT mice
compared with uninjured controls or injured St2 / mice
(Fig. 2d,e and Supplementary Fig. 3). Collagen 1 was initially
downregulated (days 1, 3) at mRNA levels (Fig. 2f) in injured WT
mice but reverted towards pre-injury levels by days 7 and 21
(Supplementary Fig. 3a) with a similar trend in Collagen 1
protein expression (Fig. 2g). In contrast, injured St2 / mice
showed prolonged reduction of collagen 1 synthesis (days 1, 3
and 7) returning to baseline only by day 21 (Supplementary
Fig. 3d). Importantly, injury of WT mice tendons resulted in a
signiﬁcant decrease in biomechanical strength at day 1 post injury
compared with that of the St2 / mice (Fig. 2h). The
biomechanical strength in all injured mice recovered by days 7
and 21 (Supplementary Fig. 3f). These data suggest altered
collagen matrix synthesis in St2 / mice implicating IL-33/ST2
as an early modulator of collagen changes in tendon injury that
has biomechanical signiﬁcance.
IL-33 modiﬁes collagen 3 expression in vivo. To conﬁrm that
IL-33 regulates collagen synthesis during tendon injury, we
sought to directly modify IL-33 effector function in vivo.
Administration of rhIL-33 did not affect collagen 1 synthesis
(Fig. 3a,b), but signiﬁcantly increased collagen 3 synthesis
particularly in injured tendons (Fig. 3c,d and Supplementary
Fig. 4a,b). Moreover, rhIL33 administration signiﬁcantly reduced
ultimate tendon strength at all time points post injection in WT
mice (Fig. 3e and Supplementary Fig. 4c,d) suggesting that such
changes were of functional impact. IL-33 administration did not
affect collagen matrix synthesis or ultimate tendon strength of the
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Figure 1 | IL-33/ST2 expression in human tendon. (a) IL-33, (b) soluble ST2 (sST2) and (c) mST2 mRNA expression in human tendon samples. Fold
change in gene expression of IL-33, sST2 and mST2 in control (semi-membranosus tendon, n¼ 10), torn supraspinatus tendon (established pathology) and
matched subscapularis human tendon samples (early pathology; n¼ 17). Data are mean±s.d. relative to the housekeeping gene18S (mean of duplicate
analysis). *Po0.05, **Po0.01, ***Po0.001 versus control (Student’s t-test). (d) Immunostaining of IL-33 and ST2 in control (n¼ 10), torn tendon (n¼ 17)
and early tendinopathy (n¼ 17). Graphs illustrate modiﬁed Bonar scoring based on 10 high-power ﬁelds. Data are mean±s.d. *Po0.05, **Po0.01 versus
control (Student’s t-test). Scale bar, 65mm. (e) Fold change in gene expression of IL33 and ST2 24h post incubation with tumour necrosis factor (TNF-a),
IL-1b or in combination depicting relative expression to media alone utilizing housekeeping gene GAPDH. Data are mean±s.d. of triplicate samples,
representative of three individual patient samples. *Po0.05, **Po0.01 versus control (media) (Student’s t-test). (f) IL-33 immunostaining of human
tendon explants cultured for 24 h with medium (control), 100 ngml 1 TNFa or 100 ngml 1 TNFaþ 100 ngml 1 IL-1b. (g) Fold change in COL1 and COL3
mRNA expression in human tendon explants cultured for 24 h with rhIL-33, relative to housekeeping gene GAPDH. (h) Time course of COL1 and COL3
mRNA expression following incubation with rhIL-33, relative to housekeeping gene GAPDH. (i) Collagen 1 and 3 protein expression in human tendon
explants 24 h post incubation with rhIL-33. For (g–i) data are mean±s.d. of triplicate samples, representative of three individual patients. *Po0.05,
**Po0.01 versus control (Student’s t-test).
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healing tendon in St2 / mice conﬁrming that IL-33 acted via
an ST2-dependent pathway (Supplementary Fig. 4).
We next directly targeted IL-33 in vivo. Neutralizing antibodies
to IL-33 attenuated the collagen 1 to 3 switch at days 1 and 3 post
injury in injured WT mice (Fig. 3f–i, Supplementary Fig. 5a)
resulting in a signiﬁcant increase in biomechanical strength at day
1 post injury in the tendons of WT mice (Fig. 3j). This effect was
not seen at later time points (Supplementary Fig. 5b). In control
experiments, we observed no effect of rIL-33 on St2 / mice
(Supplementary Fig. 5c,d). These results, therefore, further
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Figure 2 | IL-33/ST2 axis in tendon healing in vivo. Kinetics of (a) Il33 and (b) soluble St2 gene expression post injury. Data are mean fold change±s.d.
showing relative expression to 18s housekeeping gene (pooled data from four mice per group performed on four sequential occasions, n¼ 16 per condition).
*Po0.05, **Po0.01 versus control (WT) mice (ANOVA) þ Po0.05,þ þ Po0.01, NS not signiﬁcant; control (WT) injured versus St2 / injured.
(c) Immunohistochemistry showing IL-33 and ST2 expression in tendon biopsies of WTand St2 / mice day 1 post injury. IgG control shown in bottom
left of pictures. Black horizontal line indicates 50mm. (d) Col3 mRNA and (e) Collagen 3 protein levels in tendon biopsies of WT and St2 / mice post
injury. (f) Col1 mRNA and (g) Collagen 1 protein levels in tendon biopsies of WTand St2 / mice post injury. For (d–g) data are mean±s.d. of duplicate
samples, representative of four mice per condition (n¼ 16). *Po0.05, **Po0.01 versus control (WT) mice. þ Po0.05, þ þ Po0.01 control (WT) injured
versus St2 / injured mice (ANOVA). mRNA graphs show relative expression to 18s housekeeping gene. (h) Percentage change in tendon strength
for WT and St2 / mice post injury. Data are mean±s.d., representative of four mice per condition (n¼ 16). *Po0.05, **Po0.01 versus control mice.
#Po0.05 St2 / injured versus WT injured mice (Mann–Whitney U-test).
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demonstrate the contribution of endogenous IL-33 to early
injury-induced tendinopathy.
IL33 regulates collagen 3 via miR-29a in tenocytes. Having
established that IL-33 drives the differential regulation of collagen
1 and 3 in tenocytes, we postulated a mechanistic role for the
miRNA network in this process. Previous studies have shown that
the miR-29 family directly targets numerous extracellular matrix
genes, including type 1 and 3 collagens24,25 and is implicated in
the regulation of innate and adaptive immunity26. Computational
algorithms predict that miR-29 may also target sST2 (ref. 27).
We found that all members of the miR-29 family were expressed
–10
**
**
**
**
Co
ntr
ol
Co
ntr
ol +
IL3
3
Inju
red
Inju
red
 +IL
33
Co
ntr
ol
Co
ntr
ol +
IL3
3
Inju
red
Inju
red
 +IL
33
Co
ntr
ol
Co
ntr
ol +
IL3
3
Inju
red
Inju
red
 +IL
33
Co
ntr
ol
Co
ntr
ol +
 an
ti IL
-33
Inju
red
Inju
red
 + a
nti 
IL-3
3
Co
ntr
ol
Co
ntr
ol +
 an
ti IL
-33
Inju
red
Inju
red
 + a
nti 
IL-3
3
Co
ntr
ol
Co
ntr
ol +
 an
ti IL
-33
Inju
red
Inju
red
 + a
nti 
IL-3
3
Co
ntr
ol
Co
ntr
ol +
 an
ti IL
-33
Inju
red
Inju
red
 + a
nti 
IL-3
3
Co
ntr
ol
Co
ntr
ol +
 an
ti IL
-33
Inju
red
Inju
red
 + a
nti 
IL-3
3
Co
ntr
ol
Co
ntr
ol +
IL3
3
Inju
red
Inju
red
 +IL
33
Co
ntr
ol
Co
ntr
ol +
IL3
3
Inju
red
Inju
red
 +IL
33
–5
Co
l 1
 
m
R
N
A
%
 C
ha
ng
e 
in
 te
nd
on
st
re
ng
th
Co
l 1
 
m
R
N
A
Co
l 3
 
m
R
N
A
Co
lla
ge
n 
1 
(ng
 m
l–1
)
Co
l 3
 
m
R
N
A0
5 WT
St2 –/–
15
Co
lla
ge
n 
1 
(ng
 m
l–1
) 20
10
5
0
20
10
0
40
30
20
Co
lla
ge
n 
3 
(ng
 m
l–1
)
10
0
40
**
**
**
*
*
*
*
*
*
+
30
0
20
40
60
80
100
20
10
0
30
15
20
25
10
5
0
5
Day 1
Day 3
Day 1
Day 3
Day 1
Day 3
Day 1
Day 3
Day 1
Day 3
**
** **
**
0
–10
–5
15
Co
lla
ge
n 
3 
(ng
 m
l–1
)
20
25
10
5
0 0
20
40
60
%
 C
ha
ng
e 
in
 te
nd
on
st
re
ng
th
80
100
**
**
**
**
+
WT
St2 –/–
WT
St2 –/–
WT
St2 –/–
WT
St2 –/–
Figure 3 | IL-33/anti-IL-33 effects on collagen production and tendon strength in vivo. (a) Col1 mRNA, (b) Collagen 1 protein, (c) Col3 mRNA and
(d) Collagen 3 protein in WTand St2 / mice on day 1 post injury. mRNA graphs show relative expression to 18s housekeeping gene. Data are mean±s.d.
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in human tendon biopsies and explanted tenocytes (Fig. 4a) with
miR-29a showing the most altered expression in early
tendinopathy biopsies. In tenocyte culture, IL-33 signiﬁcantly
reduced the expression of miR-29a at 6, 12 and 24 h (Fig. 4b),
whereas the effect on miR-29b was modest and highly variable
(Supplementary Fig. 6a). The effect of IL-33 on miR-29a
expression was NF-kB dependent (Supplementary Fig. 6b).
Since IL-33-mediated collagen 3 matrix changes could be
regulated by miR-29a, we analysed the functional effects of
miR-29a manipulation on collagen matrix synthesis in vitro.
Using luciferase assays, we ﬁrst conﬁrmed that miR-29a directly
targets COL 1A1 and 3A1 as previously demonstrated28
(Supplementary Fig. 6c). We also observed a previously
unrecognized interaction of miR-29a with human COL 1A2
subunit transcript (Fig. 4c). To test whether miR-29a indeed
regulates the levels of candidate target mRNAs in disease relevant
cells, we transfected tenocytes with miR-29a mimic and
antagomir. miR-29a manipulation selectively regulated collagen
3 but not collagen 1 mRNA and protein expression in primary
tenocytes (Fig. 4d,e). Moreover, miR-29a overexpression
signiﬁcantly decreased IL-33-induced collagen 3 mRNA and
protein synthesis (Supplementary Fig. 6d and Fig. 4f). In
additiona, miR-29a inhibition resulted in a signiﬁcant increase
in COL 3A1 expression (Fig. 4g), indicating that miR-29a is not
only actively regulating these transcripts in human tenocytes but
its loss can be an important factor in the increase of type 3
collagen production observed in tendinopathy. In contrast, COL
1A1 and A2 transcript levels were relatively unchanged (Fig. 4g).
Given that miR-29a was capable of repressing COL 1A1 and
1A2 with equal or greater efﬁciency than collagen 3 in luciferase
reporter assays, this was unlikely to be the result of miR-29a
having greater afﬁnity for its microRNA (miRNA) recognition
element (MREs) in type 3 transcripts. One well-documented
mechanism by which transcripts modulate their sensitivity to
miRNA regulation is through the utilization of alternative
polyadenylation signals (Fig. 4h)29. Use of distal poly-
adenylation signals results in reduction in 30 untranslated
region (UTR) length with the loss of MREs. To test this, we
compared the levels of full-length (miR-29a MRE containing)
COL1A1, COL1A2 and COL3A1 transcripts expressed in human
tenocytes with their total levels by quantitative PCR (qPCR;
Fig. 4i). We found that 95% of COL1A1 and 1A2 transcripts did
not contain miR-29a MRE, whereas the majority (B75%) of
COL3A1 transcripts did. 30 rapid ampliﬁcation of complementary
DNA (cDNA ends, RACE; Supplementary Fig. 6e) conﬁrming
that both COL1A1 and 1A2 make use of previously unrecognized
polyadenylation signals (Fig. 4h). Analysis of COL3A1 30RACE
products identiﬁed transcripts containing a single miR-29a MRE
due to use of a proximal polyadenylation signal. COL3A1
luciferase constructs, which contained only this MRE, were still
efﬁciently repressed by miR-29a indicating that all COL3A1
transcripts are sensitive to regulation by miR-29a (Supplementary
Fig. 6f). Inspection of 30RACE sequences revealed the presence of
canonical polyadenylation signals upstream of polyA tails. The
resulting truncated COL1A1 and 1A2 30UTRs lack miR-29a
MREs. These data suggest that in tenocytes miR-29a speciﬁcally
regulates COL3A1, while both COL1A1 and COL1A2 are rendered
insensitive to miR-29a inhibition due to the utilisation of
alternative polyadenylation signals. Loss of miR-29a on IL-33
signalling results in the derepression of collagen 3 likely
contributing to the increase of this collagen observed in injured
tendons.
Soluble ST2 is a direct target of miR-29a. Computational
analysis revealed that miR-22, 183, 25 and 29a were predicted to
regulate sST2. However, miR-22, 183 and 25 showed much less
favourable probability in targeting sST2 (total context score
value27) than miR-29 family. Importantly, only miR-29 family
members showed a good probability in targeting both collagens
and sST2, thus suggesting a feasible regulatory role in IL-33
effector functions. A luciferase reporter gene was generated that
contains the 30UTR of human sST2 predicted to possess two
potential miR-29abc-binding sites (Supplementary Fig. 6g).
Co-transfection of sST2-luciferase reporter plasmid with miR-29
mimics in HEK 293 cells resulted in signiﬁcant reduction in
luciferase activity relative to scrambled control (Supplementary
Fig. 6h). Furthermore, luciferase activity was fully restored when
the seed regions of both miR-29 MREs in sST2 were mutated,
demonstrating that sST2 is a direct target of miR-29a (Fig. 5a).
To investigate whether miR-29a does indeed regulate the levels of
the candidate target mRNA in tenocytes, we again transfected
miR-29a mimic or antagomir into human tenocytes. Soluble
ST2 message was signiﬁcantly decreased by transfection with
miR-29a mimic and increased by antagomir (Fig. 5b), with a
corresponding signiﬁcant change in soluble ST2 protein (Fig. 5c).
These results conﬁrm soluble ST2 as a target of miR-29a. We also
noted that miR-29a mimic transfection produced no effect on the
production of rhIL-33-induced cytokines (IL-6, IL-8 and
monocyte chemoattractant protein-1; Supplementary Fig. 6i),
suggesting that miR-29a is not directly involved in the regulation
of IL-33 canonical IL-1R signalling in tenocytes.
IL-33/sST2 regulates miR-29a expression in tendon healing.
We next investigated miR-29a expression in our in vivo tendon-
healing model. Tendon injury in WT mice resulted in a 22-fold
decrease in miR-29a on day 1, which reverted to a sixfold decrease
(versus baseline) by day 3 (Fig. 5d and Supplementary Fig. 7a)
with no signiﬁcant difference by day 7. This effect was
signiﬁcantly decreased in St2 / mice (Supplementary Fig. 7a).
In addition, the administration of exogenous rhIL-33 reduced
miR-29a expression in uninjured tendons at all time points
compared with PBS-injected controls (Supplementary Fig. 7b).
This effect was most profound in injured WT mice, with the
addition of rhIL-33 mediating a further 10-fold reduction in
miR-29a (Fig. 5e). Addition of rhIL-33 in St2 / mice had no
signiﬁcant effect on miR-29a expression in injured or uninjured
tendons (Fig. 5e), again suggesting that miR-29a downregulation
is, at least in part, directly mediated by IL-33/ST2-dependent
signalling. The addition of neutralizing antibody to IL-33 sig-
niﬁcantly reduced the effect of injury on miR-29a gene expression
at days 1 and 3 post injury (Fig. 5f).
Overexpression of miR-29a regulates collagen changes in vivo.
Finally, based on our observations that the reduction of miR-29a
function was linked to collagen matrix changes in human and
animal models of tendon disease, we investigated the role of
overexpression of miR-29a in vivo in an attempt to reverse these
changes. Delivery of miR-29a mimic to the in vivo tendon-healing
model, with tissue uptake conﬁrmed by immunoﬂuorescence and
qPCR (Fig. 5g and Supplementary Fig. 7c), resulted in a sig-
niﬁcant reduction (Po0.01) of collagen 3 synthesis at days 1 and
3 post injury (Fig. 5h,i). While a transient increase in Col1
message was noted at day 1 post injury (Fig. 5j), miR-29a over-
expression caused no reduction in collagen 1 protein levels in vivo
at days 1 and 3 post injury compared with control samples
(Fig. 5k).
Discussion
miRNAs have emerged as powerful regulators of diverse cellular
processes with important roles in disease and tissue remodelling.
Studies reported here using tendinopathy as a model system
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reveal the previously unrecognized ability of a single miRNA
(miR-29a) to cross-regulate inﬂammatory cytokine effector
function and extracellular matrix in the complex early biological
processes leading to tissue repair. We also provide evidence for a
hitherto unreported role of IL-33 in the initial steps that lead to
the important clinical entity of tendinopathy.
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IL-33 has recently become increasingly associated with
musculoskeletal pathologies16. Our data show IL-33 to be
present in human tendon biopsies at the early stage of disease,
while end-stage biopsies have signiﬁcantly less IL-33 expression at
the message and protein level supporting the concept of IL-33 as
an early tissue mediator in tendon injury and subsequent tissue
remodelling. On cell injury, the so-called alarmins such as heat
shock proteins30, HMGB1 (ref. 31), uric acid32 and IL-1 family
members33,34, including IL-33 (refs 35,36), are released by both
resident immune cells and necrotic cells having undergone
damage. These alarmins are subsequently recognized by various
immune cells that initiate inﬂammatory and repair responses.
Our data implicate IL-33 as an alarmin in early tendinopathy and,
importantly, our biomechanical data suggest that such an
expression has a pathogenically relevant role. The addition of
rhIL-33 signiﬁcantly reduced the tendon strength (load to failure)
of WT mice by B30% at early time points, likely as a
consequence of the concomitant collagen 3 matrix changes,
which result in mechanically inferior tendon37. Thus, one
plausible mechanism for the events, mediating early
biomechanically inferior tendon repair, is that on repeated
micro injury IL-33 is upregulated with its subsequent release
through mechanical stress/necrosis. IL-33 then drives the matrix
degeneration and proinﬂammatory cytokine production,
propelling the tendon towards a pathological state such as that
seen in early tendinopathy biopsies. Interestingly, the addition of
IL-33-neutralizing antibodies to injured mice reversed the
collagen 3 synthesis, but this was only able to temporarily
improve tendon strength on day 1 post injury. While this may
negate blocking IL-33 in longer-term sports injuries, the repetitive
microtrauma associated with pathological tendon changes may
conversely allow neutralizing IL-33 to act as a check rein to
further unwanted matrix dysregulation. Although these results do
not exclude the contribution of other immune cells to IL-33-
mediated tendon pathology, our in vitro studies performed on
tenocytes show a robust effect of IL-33 on the differential collagen
1:3 ratio, which is replicated in the in vivo setting. Thus, while
immune cells will undoubtedly be relevant to tendon damage
in vivo, our results support the notion that tenocytes are of
substantial signiﬁcance in the IL-33-mediated changes in tendon
injury.
Emerging studies highlight miRNAs as key regulators of
leukocyte function and the cytokine network while orchestrating
proliferation and differentiation of stromal lineages that
determine extracellular matrix composition38. The ﬁnding of a
key role for miR-29a in the regulation of IL-33 ‘alarmin’-mediated
effects provides mechanistic insight into miRNA cross-regulatory
networks involving inﬂammation and matrix regulation in tissue
repair. Our data demonstrate a functional role for miR-29a as a
post-transcriptional regulator of collagen in murine and human
tendon injury. The regulation of collagens and other extracellular
matrices by the miR-29 family has been highlighted in several
prior studies25,29,39–41. Our results now suggest that miR-29a acts
as a critical repressor to regulate collagen expression in tendon
healing. Moreover, the reduced expression of miR-29a in human
biopsies suggests that its functional diminution leads to
development of tendinopathy. Despite tendon pathology being
characterized by increased collagen 3 deposition resulting in
biomechanical inferiority and degeneration, the molecular
premise for this collagen ‘switch’ has hitherto been unknown.
We describe here that IL-33-induced deﬁciency in miR-29a
results in an overproduction of collagen 3 while simultaneously
setting in motion, via sST2 inhibition of IL-33, the ultimate
resolution of this early repair process (Fig. 6). Contrary to
expectations in human tenocytes, miR-29a was only capable of
inﬂuencing the expression of COL3A1 and not type 1 collagens.
Subsequent characterization of the 30UTR of type 1 and 3
collagens revealed a previously unreported pattern of alternative
polyadenylation in both type 1 subunits, resulting in transcripts
lacking miR-29a-binding sites rendering them insensitive to
repression by this miRNA. This was not the case for type 3
collagen transcripts, which retain miR-29a-binding sites. In
human tenocytes, collagen 3 is actively repressed by miR-29a,
as demonstrated by the ability of miR-29a inhibitors to signiﬁcant
increase collagen 3 levels. Furthermore, supplementing tenocytes
with miR-29a in the presence of IL-33 was sufﬁcient to inhibit the
increased production of collagen 3. These results indicate that
miR-29a-mediated regulation of collagen 3 transcript stability is
the predominant factor in the observed increased collagen 3
IL-33 sST2
sST2↓miR-29a
ERK
Collagen 3
Collagen 3
Tenocyte
NFκB
mST2/IL-1RAcP
MyD88
Figure 6 | Schematic representation of the role of IL-33 and miR-29a in
tendon pathology. Tendon injuries or repetitive micro tears causing stress
of tendon cells result in the release of IL-33 from tenocytes or immune
cells and the downstream phosphorylation of NFkB which in turn represses
miR-29a causing an increase in collagen type 3 and sST2 production. IL-33
may also increase collagen synthesis in an ERK-dependent manner. The
increased presence of collagen 3 reduces the tendon tensile strength
lending to early tendon failure. However, elevated sST2 may act, in a
feedback loop fashion, as a protective mechanism by removing excess
IL-33 from the system.
Figure 5 | Crosstalk between IL-33/ST2 and miR-29a. (a) Luciferase activity assay of HEK 293 cells co-transferred with pre-miR-29a containing 30UTR of
WTor mutated soluble ST2 and MREs of 30UTR of soluble ST2. (n¼ 3). **Po0.01, ***Po0.001 versus scrambled control. (Student’s t-test). (b) sST2 and
mST2 mRNA levels following addition of scrambled mimic, miR-29a mimic or miR-29a antagomir in human tenocyte cultures. (n¼ 5), **Po0.01 versus
scrambled control (Student’s t-test). (c) sST2 protein production by tenocytes following incubation with miR-29a mimic/antagomir. (n¼ 5), *Po0.05
versus scrambled control. (Student’s t-test). (d) qPCR showing fold change in miR-29a in tendon of WTmice post injury. (e) qPCR showing fold change in
miR-29a in WTand St2 / mice following treatment with rhIL-33 or PBS on Day 1 post injury. (f) miR-29a expression in the tendon of WTmice post injury
with or without anti-IL-33 treatment. Data in d–f are mean fold change±s.d. of duplicate samples and are representative of four mice per group (n¼ 16),
*Po0.05, **Po0.01 versus control (ANOVA). Data for mRNA show expression relative to u6 housekeeping gene. (g) Immunoﬂuorescence stain of mimic
(red) and counterstained with phalloidin (green, for cytoskeletal structure) showing localization of mimic around tenocytes at 24 h post injection of
miR-29a mimic in WTmice. Scale bar, 80 nm. (h) Col3 mRNA, (i) Collagen 3 protein, (j) Col1 mRNA and (k) Collagen 1 protein levels post treatment with
miR-29a mimic after tendon injury in WTmice. Data for mRNA are total copy number of gene versus 18S housekeeping gene in duplicate samples. Data in
h–k are mean±s.d. of duplicate samples, representative of six mice per group, *Po0.05, **Po0.01 versus control (ANOVA).
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production. Importantly, in our model system, miR-29a
additionally targeted the IL-33 decoy receptor sST2. Thus,
IL-33-driven loss of miR-29a expression results in the
simultaneous repression of collagen 3 and sST2, with a
subsequent autoregulatory inhibition of IL-33 promoting the
resolution of the immediate alarmin response. Alternative
miRNAs have been described at various stages of the
tendinopathy spectrum42,43. While it is likely that miR29a
targets other important genes44,45 in the complex tendon
inﬂammatory/matrix mileu, our data suggest that the
reintroduction of miR-29a to the injury-induced miR-29a
deﬁciency in tendon results in reversal of the key collagen
switch that remains a core pathological feature of tendinopathy
linked to ultimate clinical tendon rupture.
On the basis of this work, we propose IL-33 as an inﬂuential
alarmin in the unmet clinical area of early tendon injury and
tendinopathy, which may be important in the balance between
reparation and degeneration. A previously unrecognized role for
miR-29a as a post-transcriptional regulator of matrix/inﬂamma-
tory genes in tendon healing and tendinopathy has been
uncovered. One of the great promises of exploiting miRNAs for
therapeutic purposes has been the potential of a single miRNA to
regulate functionally convergent target genes. Our discovery of a
single miRNA-dependent regulatory pathway in early tissue
healing highlights miR-29a replacement therapy as a promising
therapeutic option for tendinopathy with implications for other
human pathologies in which matrix dysregulation is implicated.
Methods
Human model of tendinopathy. All procedures and protocols were approved by
the Ethics Committee under ACEC No. 99/101 with informed consent obtained as
per standard operative procedures. Seventeen supraspinatus tendon (torn tendon
representing established pathology) samples (sample size based on our previous
ﬁndings of signiﬁcance with 10–12 patient samples46,47) were collected from
patients with rotator cuff tears undergoing shoulder surgery (Supplementary
Table 1). The mean age of the rotator cuff ruptured patients was 54 years (range,
35–70 years)—the mean tear size was 2.5 cm. Samples of the subscapularis tendon
(representing ‘early pathology’) were also collected from the same patients. Patients
were only included if there was no clinically detectable evidence of subscapularis
tendinopathy on a preoperative MRI scan or macroscopic damage to the
subscapularis tendon at the time of arthroscopy—by these criteria, they represented
a truly preclinical cohort. An independent control group was obtained comprising
10 samples of subscapularis tendon collected from patients undergoing
arthroscopic surgery for shoulder stabilization without rotator cuff tears. The
absence of rotator cuff tears was conﬁrmed by arthroscopic examination. The mean
age of the control group was 35 years (range, 20–41 years). All torn supraspinatus
samples showed Grade 4 changes consistent with marked degeneration, mucoid
change and frank chondroid metaplasia. Matched subscapularis tendon showed
Grade 2–3 changes indicative of moderate-advanced tendinopathy. All control
samples were classiﬁed as Grade 1 consistent with normal ﬁbrotendinous tissue
with large distinct collagen ﬁbrils. There were no signiﬁcant correlations between
Bonar score and the mean duration of symptoms or age of the patient cohort.
Tissue collection and preparation. Arthroscopic repair of the rotator cuff was
carried out using the standard three-portal technique and the cross-sectional size of
the rotator cuff tear was estimated and recorded as described previously48. The
subscapularis tendon was harvested arthroscopically from the superior border of
the tendon 1 cm lateral to the glenoid labrum. The supraspinatus tendon was
harvested from within 1.5 cm of the edge of the tear before surgical repair. For
immunohistochemical staining, the tissue samples were immediately ﬁxed in 10%
(v/v) formalin for 4 to 6 h and then embedded in parafﬁn. Sections were cut to
5 mm thickness using a Leica-LM microtome (Leica Microsystems, Germany) and
placed onto Superfrost Ultra Plus glass slides (Gerhard Menzel, Germany). Parafﬁn
was then removed from the tissue sections with xylene, rehydrated in graded
alcohol and used for histological and immunohistochemical staining according to
previously established methodologies49.
Human tendon-derived cells were explanted from hamstring tendon tissue of
ﬁve patients (aged 18–30 years) undergoing hamstring tendon anterior cruciate
ligament reconstruction. Normal tendinous structure and Bonar scoring was
ensured by histology before inclusion. Cultures were maintained at 37 C in a
humidiﬁed atmosphere of 5% CO2 for 28 days. Cells were subcultured and
trypsinized at subconﬂuency. Cells from the third and fourth passage were used
and tenocyte lineage was conﬁrmed by tenascin C, CD55 and scleraxis staining as
per our previous protocols46.
We recognize the limitations of anatomical, environmental and biomechanical
differences between rotator cuff and hamstring tendons. However, our rationale
behind using these models is based on our previous reports utiliszng the same
systems23,46 and ultimately, within the ﬁeld, they remain the ‘gold standard ‘
for allowing comparative molecular investigation of the early events in tendon
injury/disease50.
Histology and immunohistochemistry. Human tendon sections were stained
with haematoxylin and eosin and toluidine blue for determination of the degree of
tendinopathy as assessed by a modiﬁed version of the Bonar score51 (Grade 4,
marked tendinopathy; 3, advanced tendinopathy; 2, moderate degeneration; 1, mild
degeneration; 0, normal tendon). This included the presence or absence of oedema
and degeneration together with the degree of ﬁbroblast cellularity and chondroid
metaplasia. Thereafter, the sections were stained with antibodies directed against
the following markers:—IL-33 (Alexis ALX-804–840, mouse monoclonal
5 mgml 1), ST2 (R&D Systems, Europe, Clone 97203, mouse monoclonal
15 mgml 1), IL-1RaCP (ProSci 2131, rabbit polyclonal 5 mgml 1), CD68 (pan
macrophages, clone KP-1, Vector 1 mgml 1), CD3 (T cells, cone LN10, Vector
Labs 1.25 mgml 1), CD4 (T helper cells clone 1F6, Dako Labs 1 mgml 1), CD206
(M2 macrophages, R&D Systems, AF2534 5 mgml 1) and mast cell tryptase (Mast
cells clone 10D11, Vector Labs 1 mgml 1).
Endogenous peroxidase activity was quenched with 3% (v/v) H2O2, and
nonspeciﬁc antibody binding blocked with 2.5% horse serum in TBST
(Tris-buffered saline with Tween 20) buffer for 30min. Antigen retrieval was
performed in 0.01M citrate buffer for 20min in a microwave. Sections were
incubated with primary antibody in 2.5% (w/v) horse serum/human serum/TBST
at 4 C overnight. After two washes, the slides were incubated with Vector
ImmPRESS Reagent kit as per the manufacturer’s instructions for 30min. The
slides were washed and incubated with Vector ImmPACT DAB chromagen
solution for 2min, followed by extensive washing. Finally, the sections were
counterstained with haematoxylin. Positive (human tonsil tissue) specimens were
included, in addition to the surgical specimens for each individual antibody
staining technique. Omission of primary antibody and use of negative control
isotype conﬁrmed the speciﬁcity of staining.
We applied a scoring system based on previous methods47 to quantify the
immunohistochemical staining. Ten random high power ﬁelds ( 400) were
evaluated by three independent assessors (N.L.M., J.H.R., A.L.C.). In each ﬁeld, the
number of positive and negatively stained cells were counted and the percentage of
positive cells calculated giving the following semi-quantitative grading; Grade 0,
no staining; Grade 1,o10% cells stained positive; 2, 10–20% cells stained positive;
Grade 3, 420% cells positive.
Mouse tendon sections were processed using the above protocol with antibodies
directed against the following markers:—IL-33 (R&D systems AF3626, mouse
monoclonal), ST2 (R&D Systems Clone 97203, mouse monoclonal 15 mgml 1)
and F4/80 (Serotec clone CI:A3-1, mouse monoclonal 20 mgml 1)).
Matrix regulation. Total soluble collagen was measured from cell culture super-
natants using the Sircol assay kit (Biocolor, Carrickfergus, Northern Ireland)
according to the manufacturer’s protocol. Sircol dye reagent (1ml) was added to
test sample (100 ml) and mixed for 30min at room temperature. The collagen–dye
complex was precipitated by centrifugation at 10,000g for 10min and then washed
twice with 500 ml of ethanol. The pellet was dissolved in 500 ml of alkali reagent.
Absorbance was measured by microplate reader at 540 nm, with standard provided
by the manufacturer. The concentrations of human and mouse collagen 1 and 3
were assessed using ELISA (USCNK Life Science Inc) with colour change measured
at 450 nm by microplate reader, along with standards supplier by the manufacturer.
Signalling experiments. Phosphorylation status of MAPKs (mitogen-activated
protein kinases), extracellular signal regulated kinases (ERK1/2), c-Jun N-terminal
kinases (JNKs) and p38 isoforms were evaluated using the Human Phospho-
MAPK Array (R&D Systems) as per the manufacturer’s instructions. The ERK
inhibitor (FR180204) was purchased from CalbioChem (Merck KGaA, Germany)
and used at IC50¼ 10 mM, a concentration previously determined to offer optimal
speciﬁc inhibition relative to off target effects, which was used previously in our
laboratory52.
Phosphorylation of NF-kB p65 was assessed using the InstantOne ELISA in cell
lysates from treated and untreated tenocytes. Absorbance was measured at 450 nm
by microplate reader with positive and negative controls supplied by the
manufacturer. The relative absorbance of stimulated versus unstimulated cells was
used to assess the total or phosphorylated NF-kB p65 in each sample. The NF-kB
inhibitor (SN50) was purchased from CalbioChem (Merck KGaA, Germany) and
used at IC50¼ 11 nM.
RNA extraction and quantitative PCR. The cells isolated from experiments were
placed in Trizol before mRNA extraction. QIAgen mini columns (Qiagen) were
used for the RNA clean-up with an incorporated on column DNAse step as per the
manufacturer’s instructions. cDNA was prepared from RNA samples according to
AfﬁnityScript (Agilent Technologies) multiple temperature cDNA synthesis kit as
per the manufacturer’s instructions. Real-time PCR was performed using SYBR
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green or Taqman FastMix (Applied Biosystems,) according to whether a probe was
used with the primers. The cDNA was diluted 1 in 5 using RNase-free water. Each
sample was analysed in triplicate. Primers (Integrated DNA Technologies,
Belgium) were as follows: human GAPDH, 50-TCG ACA GTC AGC CGC ATC
TTC TTT-30 (f) and 50-ACC AAA TCC GTT GAC TCC GAC CTT-30 (r); mouse
Gapdh 50-TGG CAA AGT GGA GAT TGT TGC C-30 (f) and 50-AAG ATG GTG
ATG GGC TTC CCG-30 (r); human 18S, 50-GTA ACC CGT TGA ACC CCA
TT-30 (f) and 50-CCA TCC AAT CGG TAG TAG CG -30 (r); mouse 18s, 50-TTG
ACG GAA GGG CAC CAC CAG-30 (f) and 50-CTC CTT AAT GTC ACG CAC
GAT TTC-30 (r); human U6, 50-GTG CTC GCT TCG GCA GCA CAT ATA C-30
(f) and 50-AAA AAT ATG GAA CGC TTC ACG AAT TTG-30 (r); human IL33,
50-GGA AGA ACA CAG CAA GCA AAG CCT-30 (f) and 50-TAA GGC CAG
AGC GGA GCT TCA TAA-30 (r); murine Il33, 50-GGA AGA ACA CAG CAA
GCA AAG CCT-30 (f) and 50-TAA GGC CAG AGC GGA GCT TCA TAA-30 (r);
total human ST2, 50-ACA ACT GGA CAG CAC CTC TTG AGT-30 (f) and
50-ACC TGC GTC CTC AGT CAT CAC ATT-30 (r); murine sSt2, 50-CCA ATG
TCC CTT GTA GTC GG (f) and CTT GTT CTC CCC GCA GTC (r), TCC CCA
TCT CCT CAC CTC CCT TAA T-30 (probe); mouse mSt2, 50-TCT GCT ATT
CTG GAT ACT GCT TTC-30 (f) and 50-TCT GTG GAG TAC TTT GTT CAC
C-30 (r), 50-AGA GAC CTG TTA CCT GGG CAA GAT G-30 (probe); human
mST2, 50-ACA AAG TGC TCT ACA CGA CTG-30 (f) and 50-TGT TCT GGA
TTG AGG CCA C-30 (r); 50-CCC CAT CTG TAC TGG ATT TGT AGT TCC G-30
(probe); human sST2, 50-GAG ACC TGC CAC GAT TAC AC-30 (f) and 50-TGT
TAA ACC CTG AGT TCC CAC-30 (r), 50-CCC CAC ACC CCT ATC CTT
TCT CCT-30 (probe); human COL3A, 50-TTG GCA GCA ACG ACA CAG AAA
CTG-30 (f) and 50-TTG AGT GCA GGG TCA GCA CTA CTT-30 (r); mouse Col3a,
50-GCT TTG TGC AAA GTG GAA CCT GG-30 (f) and 50-CAA GGT GGC TGC
ATC CCA ATT CAT-30 (r); human COL1A1, 50-CCA TGC TGC CCT TTC TGC
TCC TTT-30 (f) and 50-CAC TTG GGT GTT TGA GCA TTG CCT-30 (r); mouse
Col 1a1, 50-TTC TCC TGG CAA AGA CGG ACT CAA-30 (f) and 50-GGA AGC
TGA AGT CAT AAC CGC CA-30 (r). All mRNA and miRNA data sets (except
Fig. 4a) represent fold change in gene expression compared with designated control
utilizing housekeeping genes GAPDH, 18S or U6 as detailed in Figure legend.
Figure 4a shows threshold cycle (Ct) data for miR-29a/b/c expression in human
tenocytes and human tendon tissue samples. Lower Ct value represents higher
message abundance.
RNA isolation and quantitative PCR of miRNA. Total RNA was isolated by
miRNeasy kit (Qiagen). miScript Reverse Transcription Kit (Qiagen) was used for
cDNA preparation. TaqMan mRNA assays (Applied Biosystems) or miScript
primer assay (Qiagen) were used for quantitative determination of the expression
of human miR-29a (MS00001701) miR-29b (MS00006566) and miR-29c
(MS00009303) and mouse miR-29a (MS00003262), miR-29b (MS00005936) and
miR-29c (MS00001379). Expressions of U6B small nuclear RNA or b-actin were
used as endogenous controls.
Quantiﬁcation of alternative polyadenylated collagen transcripts. The absolute
levels of long and short 30UTR forms of type I and III transcripts were determined
by qPCR relative to standards. cDNA was generated using AfﬁnityScript (Agilent)
with both random hexamer and oligo-dT primers. SYBR green qPCR was
performed using the following primers: Samples were normalized to GAPDH
endogenous control.
COL1A2_S FW 50-GCCTGCCCTTCCTTGATATT-30
COL1A2_S REV 50-TGAAACAGACTGGGCCAATG-30
COL1A2_L FW 50-TCAGATACTTGAAGAATGTTGATGG-30
COL1A2_L REV 50-CACCACACGATACAACTCAATAC-30
COL1A1_S FW 50-CTTCACCTACAGCGTCACT-30
COL1A1_S REV 50-TTGTATTCAATCACTGTCTTGCC-30
COL1A1_L FW 50-CCACGACAAAGCAGAAACATC-30
COL1A1_L REV 50-GCAACACAGTTACACAAGGAAC-30
COL3A1_S FW 50-CTATGACATTGGTGGTCCTGAT-30
COL3A1_S REV 50-TGGGATTTCAGATAGAGTTTGGT-30
COL3A1_L FW 50-CCACCAAATACAATTCAAATGC-30
COL3A1_L REV 50-GATGGGCTAGGATTCAAAGA-30
30RACE. 30RACE was performed on RNA that had been reverse transcribed
using AfﬁnityScript (Agilent) by sequence tagged oligo-dT primers (QT, Q0 Q1).
30 sequences were then ampliﬁed using nest-PCR approach with gene-speciﬁc
primers (GSP 1/2). Ampliﬁed products were cloned into pCR2.1TOPO
(Invitrogen) and sequenced.
QT 50-CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCTTTTTTTT
TTTTTTTTT-30
Q0 50-CCAGTGAGCAGAGTGACG-30
Q1 50-GAGGACTCGAGCTCAAGC-30
COL1A1 GSP1 50-CTTCCTGTAAACTCCCTCCATC-30
COL1A1 GSP2 50-AACAGACAAGCAACCCAAAC-30
COL1A2 GSP1 50-CAGACAAGCAACCCAAACTG-30
COL1A2 GSP2 50-AATGGGAGACAATTTCACATGG-30
COL3A1 GSP1 50-GCCTGCCCTTCCTTGATATT-30
COL3A1 GSP2 50-CCTTCCATTTCTTCTGCACATC-30
miRNA transfection. Cells (primary tenocytes) were transfected with synthetic
mature miRNA for miR-29a and b or with negative control (C. elegans miR-67
mimic labelled with Dy547, Thermo Scientiﬁc Inc.) at a ﬁnal concentration of
20 nM with the use of Dharmacon DharmaFECT 3 siRNA transfection reagents
(Thermo Scientiﬁc Inc.). At 48 h after transfection, the cellular lysates were
collected to analyse the expression of genes of interest.
Transfection efﬁciency (80%) was assessed by ﬂow cytometry using the labelled
Dy547 mimic (Supplementary Fig. 7g) and conﬁrmed by qPCR of control-
scrambled mimic and the respective miR29 family mimic.
Luciferase reporter assay for targeting collagen 1 and 3 and soluble ST2. The
human 2 miRNA target site was generated by annealing the oligos: for COL 1 and 3
and soluble ST2 30UTRs that were cloned in both sense and antisense orientations
downstream of the luciferase gene in pMIR-REPORT luciferase vector (Ambion).
These constructs were sequenced to conﬁrm inserts and named pMIR-COL I/COL
III/ sST2-miR29a/b/c and pMIR(A/S)-COL I/COL III/ sST2-miR29a/b/c, and used
for transfection of HEK293 cells (HEK293 cells tested negative for mycoplasma
before use). HEK293 cells were cultured in 96-well plates and transfected with
0.1 mg of either pMIR-COL I/COL III/ sST2-miR29a/b/c, pMIR(A/S)-COL I/COL
III/ sST2-miR29a/b/c or pMIR-REPORT, together with 0.01 mg of pRL-TK vector
(Promega) containing Renilla luciferase and 40 nM of miR-29a or scrambled
miRNA (Thermo Scientiﬁc Dharmacon). Transfections were performed using
Effectene (Qiagen) according to the manufacturer’s instructions. Luciferase activity
was measured 24 h after transfection using the Dual-Luciferase Reporter Assay
(Promega). The 30UTR of human sST2 was ampliﬁed from genomic DNA using the
following primers (f) 50-AGTTTAAACTGGCTTGAGAAGGCACACCGT-30 and
(r) 50-AGTCGACGGGCCAAGAAAGGCTCCCTGG-30 , which created PmeI and
SalI sites, respectively. These sites where used to clone the PCR-ampliﬁed product
into the same sites of pmiRGLO (Promega). The seed regions of the two Targetscan
predicted miR-29a MRE sites: 29-1 and 29-2 were mutated using the QuickChange
site-directed mutagenesis kit (Agilent). Each vector along with miR-29a or
scrambled control mimic were transfected into HEK293 cells using Attactene
(Qiagen) according to the manufacturer’s instructions. Luciferase activity was
measured 24 h later using Dual-Glo luciferase assay (Promega) with luciferase
activity being normalized to Renilla. Normalized luciferase activity was expressed
as a percentage of scrambled control for the same constructs.
Cytokine production. Cytokine concentration in the supernatant of cultured
human tenocytes was determined by 25-Plex human cytokine assay (with 25
separate human cytokines) using Luminex (Luminex Corp).
Animals and patellar tendon injury model. BALB/c mice were purchased from
Charles River. St2 / mice (of BALB/c background) were originally provided by
Dr Andrew McKenzie (LMB, Cambridge). Mice were maintained at the Central
Research Facility, University of Glasgow. All animal experimentation and hus-
bandry were according to the UK Government Home Ofﬁce Project License. All
protocols were approved by the Glasgow University local Ethical Review Panel.
Mice were used at 10–12 weeks old and were age matched for each independent
experiment. In vivo experimental protocols are depicted in Supplementary
Fig. 7e,f,h).
In preparation for the surgical procedure, mice were anaesthetized with a
mixture of isoﬂuorane (3%) and oxygen (1%) and both hind limbs were shaved.
During surgical procedures, anaesthesia was delivered via a nose cone with the level
of isoﬂuorane reduced to 1% with oxygen. Following a skin incision, two cuts
parallel to the tendon were made in the retinaculum on each side, a set of ﬂat faced
scissors were then placed underneath the patellar tendon. With the scissor blades
serving as a support, a 0.75-mm diameter biopsy punch (World Precision
Instruments) was used to create a full thickness partial transection in the right
patellar tendon. The left patellar tendon underwent a sham procedure, which
consisted of only placing the plastic backing underneath the tendon without
creating and injury. The skin wounds were closed with skin staples and the mice
were killed at day 1, 3, 7 or 21 post surgery. Mice were killed by CO2 inhalation and
immediately weighted. Each group contained 16 mice (n¼ 8, St2 / and 8 WT)
per time point. These experiments were repeated on four separate occasions.
To test if IL-33 induced tendon matrix dysregulation, a cytokine injection
model was used. IL-33 was tested in a previously reported model initially described
for the application of IL-23 or IL-22 (refs 53,54). St2 / mice (n¼ 4 per group/
treatment/experiment) were injected intraperitoneally daily with IL-33 (0.4 mg per
mouse diluted in 100 ml PBS) on days  3,  2,  1 and the day of injury (day 0).
Mice were culled 24 h after the ﬁnal injection as per protocol. Control mice
similarly received an equal volume of PBS. We also tested neutralizing antibodies to
IL-33 (0.5 mgml 1, R&D systems) by injecting (i.p) the antibody or normal IgG
control immediately post injury in WT and St2 / mice (four per group/
treatment/experiment).
miR-29a mimic (50 ngml 1 in 0.1ml) was delivered via direct injection to
injured (immediately post injury) and uninjured mice tendons (n¼ 6 per group/
treatment/experiment). Control mice similarly received an equal volume of PBS.
During these procedures, the GCP principles were applied. All samples were
labelled in a numerical fashion and were then blinded during all further
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experimental methodology. Numerical codes were only revealed post experiment
and analysis.
Biomechanical analysis. For biomechanical analysis, the patellar tendons of mice
from each group were injured and eight mice killed at one of the four time points
for mechanical testing as described previously by Lin et al.10 (Supplementary
Fig. 7f). On the basis of previous experiments, a sample size of eight per group
offered 95% conﬁdence interval that a 50% difference between injured and control
littermate animals would be detected.
In brief, the patellar tendons were dissected and cleaned, leaving only the
patella, patellar tendon and tibia as one unit. Tendon width and thickness were
then quantiﬁed and cross-sectional area was calculated as the product of the two.
The tibia was then embedded in Isopon p38 (High Build Cellulose Filler) in a
custom-designed ﬁxture and secured in place in a metal clamp. The patella was
held in place by vice grips used with the BOSE ElectroForce 3200 test instrument.
Each tendon specimen underwent the following protocol immersed in a 37 C
saline bath—reloaded to 0.02N, preconditioned for 10 cycles from 0.02 to 0.04 at a
rate of 0.1% s 1 (0.003mm s 1), and held for 10 s. Immediately, a stress relaxation
experiment was performed by elongating the tendon to a strain of 5% (0.15mm) at
a rate of 25% (0.75mm/s), followed by a relaxation for 600 s. Finally, a ramp to
failure was applied at a rate of 0.1% s 1 (0.003mm s 1). From these tests,
maximum stress was determined and modulus was calculated using linear
regression from the near linear region of the stress strain curve.
Statistical analysis. All results are shown as mean±s.d. and all statistical analysis
was performed using Student’s t-test, ANOVA (analysis of variance) test or
Mann–Whitney test U-test, as indicated in ﬁgure legends, using the Graph Pad
Prism 5 software. A P value of o0.05 was considered statistically signiﬁcant.
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